Vincent Viviani

Vincent Viviani was born in Paris (France). After spending 3 years in Tahiti (French Polynesia), he returned to France for College. In 2013, he obtained his B.S. in Chemistry and Biology (Pr. Rachid Barhdadi) from the Université Paris-EST Créteil (France). During his undergraduate studies, he participated in the development of an induction model of Parkinson's Disease by the synthesis of pyridinium derivatives (Centre National pour la Recherche Scientifique - ICMPE Thiais). In 2015, he obtained his M.S. in Chemistry of Bioactive Molecules (Pr. Sylvie Condon) at the same university where he worked in a pharmaceutical company, Sanofi, in the Chemical Development Department on the synthesis and development of cationic lipid nanoparticles for sRNA in vivo delivery. In 2017, he finished his M.Eng. in Chemical Engineering at Chimie Paris-Tech (ENSCP - France) (Pr. Christophe Thomas). Then, he worked for one year in the Integrated Drug Discovery Department at Sanofi (France), where he worked on synthesizing therapeutic targets over diverse fields (oncology, rare diseases, cardiovascular, etc.). In August 2018, he joined the Hull Group at the University of Texas at Austin. He got his Ph.D. in transition metal-catalyzed difunctionalization reactions of olefins in September 2024.